Nautilus Biotechnology Lays Off 16% of Staff, Postpones Proteome Platform Launch to Late 2026

Nautilus Biotechnology laid off 16% of its workforce to extend its cash runway into 2027 and delayed the commercial release of its proteome analysis platform until late 2026. The company aims to control operating expenses and maximize its impact on biological science, focusing on proteomics to advance drug development.